{"entity":{"id":"nct01594723","kind":"trial","name":"A Study of LY2784544 in Participants With Myeloproliferative Neoplasms","aka":[],"tldr":"A phase 2 trial of 120 mg LY2784544 in myeloproliferative neoplasms, run by Eli Lilly and Company, active and no longer recruiting.","summary":"A Study of LY2784544 in Participants With Myeloproliferative Neoplasms is a phase 2 interventional study registered as NCT01594723 by Eli Lilly and Company, with 110 participants enrolled, started 2012-05-22 and due to reach its primary completion in 2015-03-20. Interventions recorded: 120 mg LY2784544.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT01594723","url":"https://clinicaltrials.gov/study/NCT01594723"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT01594723","phase":"2","setting":"A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms","sponsor":"Eli Lilly and Company","enrolled":110,"outcomes":[]},"route":"/trials/nct01594723/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}